Instinet: “Time To “Reduce” Alnylam Pharmaceuticals (NDAQ:ALNY)”

September 17, 2017 - By reb123z

 Instinet: “Time To

Investors sentiment decreased to 0.77 in Q4 2016. Its down 0.25, from 1.02 in 2016Q3. It turned negative, as 64 investors sold Alnylam Pharmaceuticals, Inc. shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported.

California State Teachers Retirement Systems owns 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 156,090 shares. Washington Natl Bank reported 11 shares or 0% of all its holdings. Blackrock Investment Mngmt Limited Liability reported 36,732 shares. Qs Limited Liability Corp invested in 8 shares or 0% of the stock. Sectoral Asset Incorporated, Quebec – Canada-based fund reported 19,899 shares. Daiwa Sb Invs invested in 8,111 shares. New York-based Bancorp Of Ny Mellon Corporation has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Manufacturers Life Insur Company The has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,374 shares. Td Asset accumulated 92,800 shares or 0.01% of the stock. Oxford Asset has 19,723 shares. Moreover, Mitsubishi Ufj Tru And Bk has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). California Employees Retirement Sys accumulated 0.01% or 115,600 shares. Ckw Fincl Grp Inc invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Ibm Retirement Fund holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 6,020 shares. Hall Laurie J Trustee reported 0.1% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since May 15, 2017, it had 2 insider purchases, and 3 insider sales for $17.81 million activity. Sanofi bought $21.38M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, May 31. KEATING LAURIE bought 11,500 shares worth $751,502. $2.84M worth of stock was sold by Vaishnaw Akshay on Monday, May 15.

How Instinet Currently Rates Alnylam Pharmaceuticals (NDAQ:ALNY)

Instinet made public in a report that it began coverage on Alnylam Pharmaceuticals (NDAQ:ALNY) stock, with “Reduce” rating.

Investors sentiment decreased to 0.77 in Q4 2016. Its down 0.25, from 1.02 in 2016Q3. It turned negative, as 64 investors sold Alnylam Pharmaceuticals, Inc. shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported.

California State Teachers Retirement Systems owns 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 156,090 shares. Washington Natl Bank reported 11 shares or 0% of all its holdings. Blackrock Investment Mngmt Limited Liability reported 36,732 shares. Qs Limited Liability Corp invested in 8 shares or 0% of the stock. Sectoral Asset Incorporated, Quebec – Canada-based fund reported 19,899 shares. Daiwa Sb Invs invested in 8,111 shares. New York-based Bancorp Of Ny Mellon Corporation has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Manufacturers Life Insur Company The has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,374 shares. Td Asset accumulated 92,800 shares or 0.01% of the stock. Oxford Asset has 19,723 shares. Moreover, Mitsubishi Ufj Tru And Bk has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). California Employees Retirement Sys accumulated 0.01% or 115,600 shares. Ckw Fincl Grp Inc invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Ibm Retirement Fund holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 6,020 shares. Hall Laurie J Trustee reported 0.1% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since May 15, 2017, it had 2 insider purchases, and 3 insider sales for $17.81 million activity. Sanofi bought $21.38M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, May 31. KEATING LAURIE bought 11,500 shares worth $751,502. $2.84M worth of stock was sold by Vaishnaw Akshay on Monday, May 15.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 2 analysts covering Alnylam Pharmaceuticals (NDAQ:ALNY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Alnylam Pharmaceuticals has $110 highest and $55 lowest target. $82.50’s average target is 8.25% above currents $76.21 stock price. Alnylam Pharmaceuticals had 2 analyst reports since March 30, 2017 according to SRatingsIntel. On Monday, May 15 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Neutral” rating by UBS on Thursday, March 30.

The stock decreased 2.48% or $1.94 on September 15, reaching $76.21. About 1.35 million shares traded or 43.88% up from the average. Alnylam Pharmaceuticals, Inc. (NDAQ:ALNY) has risen 33.54% since September 17, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Wall Street await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to release earnings on November, 1. Analysts forecast EPS of $-1.18, up exactly $0.03 or 2.48 % from 2014’s $-1.21 EPS. After posting $-1.34 EPS for the previous quarter, Alnylam Pharmaceuticals, Inc.’s analysts now forecast -11.94 % EPS growth.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $7.17 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Nomura bearish on Alnylam; sees 28% downside risk” on September 15, 2017, also Nasdaq.com with their article: “Alnylam Pharma Suspends Fitusiran Dosing – Quick Facts” published on September 07, 2017, Businesswire.com published: “INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam …” on September 08, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam Pharmaceuticals’ (ALNY) CEO John Maraganore Presents At Morgan Stanley …” published on September 13, 2017 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.